The Dermatology Digest

OCTOBER 16, 2024

Gross’s work, Georgia is taking proactive steps to accurately define “cosmetic laser services” and ensuring these medical procedures are considered the practice of medicine to best protect patients. We appreciate their hard work and dedication to promoting and protecting patient safety.

Safety 36

Safety Surgery Office Dermatology 36

The Dermatology Digest

NOVEMBER 6, 2024

. “The new Translational Bridge Award addresses a critical gap in lupus research, enabling scientists to bring their most promising ideas closer to people living with lupus,” says Teodora Staeva, PhD, LRA Vice President and Chief Scientific Officer, in a news release.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

MARCH 14, 2025

. “At the NFL, we’re always looking for new ways to provide the highest level of care to our players, including through collaboration with experts across the medical field.

Pharmaceutical 36

Pharmaceutical Partnerships Medical Office 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Dr. Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. View this post on Instagram A post shared by News Reviews Education for Skin Pros (@lipgloss_aftershave) 5.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

The Dermatology Digest

JANUARY 22, 2025

We are excited to partner with Revance to further clinical development of our unique program, using our Xyngari product for a needle-free, intradermal delivery of a botulinum toxin, like Daxxify, to the dermis, says Gerald Proehl, Chairman, President, and Chief Executive Officer of Dermata, in a news release.

Injections 36

Injections Office Clinic Partnerships 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

JANUARY 5, 2024

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea. The post Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29 appeared first on The Dermatology Digest.

Rosacea 36

Rosacea Medical Office Clinic 36

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

Aesthetics Advisor

FEBRUARY 1, 2024

Medical errors remain a leading cause of death in the U.S., 2 Describing diagnostic errors as "the most under-resourced public health crisis we face," researchers with Johns Hopkins School of Medicine said the public is largely unaware of the full scope of medical misdiagnoses in the U.S. 6 For instance, only about 1.5%

Medical 36

Medical Hospital Safety Training 36

The Dermatology Digest

FEBRUARY 10, 2025

FDA’s Fast Track designation is granted to investigational therapies that treat serious conditions and have the potential to address an unmet medical need. Senior Vice President and Chief Research & Development Officer at Nektar, in a news release.

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

JANUARY 14, 2024

Zoryve foam was well-tolerated with a favorable safety and tolerability profile. As the first topical drug approved with a new mechanism of action for this condition in 20 years, foam represents an important advancement in treatment and addresses a truly significant need in this population.”

Dermatitis 72

Dermatitis Office Dermatology Safety 72

North Dallas Dermatology Associates

NOVEMBER 1, 2023

One misconception is cosmetic procedures are the same everywhere, from a local spa to a board-certified physician’s office. After all, who wouldn’t want to be in the capable hands of a medical professional? Many medical spas are unable to provide medical oversight to handle complications that may arise during a procedure.

Office 36

Office Safety Medical Training 36

Natural Beauty Med Spa

APRIL 28, 2024

However, you might be reluctant to commit to it due to concerns about safety. The most important thing you should do is entrust yourself to a qualified aesthetic medical team. Safety is of the utmost importance to us, and we take every reasonable precaution to protect our patients. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Dermatology Digest

APRIL 9, 2025

This tip ensures a controlled treatment environment, increasing treatment efficacy and patient safety. Wang, MD, MBE, MBA, who is the Medical Director of Laser & Skin Surgery Center of Pennsylvania and Medical Research Director at the office of Roy Geronemus, MD.

Technology 36

Technology Office Surgery Safety 36

The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified. The study appears in the Aesthetic Surgery Journa l. “The The study appears in the Aesthetic Surgery Journa l.

Safety 36

Safety Office Surgery Dermatology 36

New Age Spa Institute

APRIL 18, 2024

In the field of medical aesthetics, lasers are used primarily for hair removal, promoting the destruction of hair follicles and sealing off the vessels that feed hair bulbs. LASER treatments are classified as medical procedures due to their invasive nature and the specific training required to operate these powerful devices.

Legal 40

Legal Hair Removal Esthetician Safety 40

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Topical or systemic AD medications were not permitted during the study. and Canada. with IGA=4.

Safety 36

Safety Therapy Dermatitis Eczema 36

AAAMS

MARCH 19, 2022

Dentists and dental hygienists perform high-level procedures in the office, making them capable of performing Botox. Additionally, Botox can treat medical conditions along with cosmetic preferences. Getting ahead of the popular trend can help your office aid patients when others cannot.

Training 52

Training Injections Facials Medical 52

The Beauty Brains

MARCH 4, 2019

They also have advice from a body called the scientific committee for cosmetic safety or SCCS, which is composed largely of academics with an interest in medicine and general science. Its stated purpose is to provide poisons centres with rapid information on the ingredients of cosmetic products in the event of some kind of medical incident.

Safety 52

Safety Cosmetic Products Pharmaceutical Ingredients 52

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

MAY 9, 2024

Data from both trials demonstrated a consistent, favorable safety and tolerability profile with no treatment-related serious adverse events (SAEs) or SAEs leading to discontinuation reported in imsidolimab-treated patients. Anaptys plans to submit a data abstract for GEMINI-1 and GEMINI-2 results to a medical meeting later this year.

Office 36

Office Medical Safety Therapy 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 36

Safety Office Dermatitis Clinic 36

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. With Volux, medical professionals have a new option for providing results and increased support and structure for the cheeks, chin, and jawline.

Training 36

Training Injections Medical Facials 36

The Dermatology Digest

AUGUST 14, 2024

The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. It’s very, very exciting data.”

Pharmaceutical 36

Pharmaceutical Safety Clinic Scarring 36

The Dermatology Digest

FEBRUARY 27, 2024

. “The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

SEPTEMBER 30, 2024

The OLE results continue to show that ESK-001 has the potential to safely and effectively inhibit the TYK2 target at the 40mg twice daily dose and deliver lasting benefits that improve over time with continued treatment,” says Dr. Jörn Drappa, Alumis’ Chief Medical Officer, in a news release.

Clinic 36

Clinic Safety Sustainability Office 36

The Studio Academy of Beauty

FEBRUARY 27, 2023

Career Opportunities: Becoming a facialist provides access to numerous job opportunities within the beauty industry including spas, salons, medical offices and more. This includes completing any required courses or workshops related to safety and sanitation practices, as well as any other topics specified by the board.

Continuing Education 52

Continuing Education Continuous Education Chemical Peels Sanitation 52

The Dermatology Digest

JANUARY 24, 2024

It is a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules. No specific treatment-emergent safety concerns were identified for delgocitinib cream, and the overall safety profile was consistent with what was observed in DELTA 1, 2 and 3.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

JANUARY 14, 2024

INTEGUMENT-1 and INTEGUMENT-2 (The INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis) were two identical Phase 3, parallel-group, double-blind, vehicle-controlled trials evaluating the safety and efficacy of roflumilast cream 0.15% in AD. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36